Wholeleaf is set to secure ₹7.5 crore in fresh funding as the pain therapeutics startup accelerates its expansion across India’s rapidly growing health and wellness market. The Gurugram-based company is currently in advanced discussions with institutional investors IPV and Benzai 10 Capital, marking another important milestone in its growth journey.
The funding development has emerged as a notable story in D2C news India, D2C startup news, and Indian D2C updates, highlighting growing investor confidence in science-backed wellness brands that are solving large consumer health challenges through innovation, research, and distribution scale.
Founded in 2021 by Shivraj Sharma, Wholeleaf operates in the chronic pain management segment with a portfolio of natural pain therapeutics designed to address conditions such as migraines, arthritis, fibromyalgia, menstrual pain, anxiety, sleeplessness, and chronic neuropathic pain. The company has positioned itself at the intersection of healthcare innovation and consumer wellness, creating a differentiated offering within India’s rapidly evolving D2C ecosystem India.
Prior to this funding round, Wholeleaf secured ₹1.5 crore on Shark Tank India from investors Aman Gupta, Kanika Tekriwal, and Namita Thapar. The company had also raised ₹3.5 crore from ah! Ventures and angel investors, taking its total funding to ₹5 crore before the proposed investment. The latest round further strengthens Wholeleaf’s position among the latest D2C startups attracting investor attention within India’s wellness and healthcare sectors.
The fresh capital will be utilized to expand the company’s offline retail footprint, strengthen product development, accelerate distribution, and increase brand visibility across online and offline channels. These initiatives align closely with broader D2C expansion plans and omnichannel D2C strategy trends that are shaping the future of D2C business India.
Wholeleaf currently has a presence across nearly 2,000 retail outlets, primarily concentrated in Delhi-NCR. The company now plans to expand its retail network to between 5,000 and 7,000 outlets over the coming year while deepening its presence across key Tier I and Tier II markets, including Bengaluru, Mumbai, Hyderabad, Kolkata, Ahmedabad, Goa, and Chennai. This aggressive expansion strategy reflects growing demand for evidence-based wellness solutions and highlights evolving D2C consumer behavior India.
The startup reports an annual recurring revenue (ARR) of approximately ₹18 crore and has established itself as a category leader in cannabinoid-based pain therapeutics. Its growth has been supported by a physician-led product development process that emphasizes safety, efficacy, regulatory compliance, and scientific validation. According to the company, every formulation undergoes multi-stage validation, including safety testing, pilot studies, and third-party government-certified laboratory assessments.
India’s wellness sector continues to create significant opportunities for innovative D2C wellness startups and premium D2C brands India that focus on solving real consumer problems. Rising health awareness, increasing demand for preventive care, and growing acceptance of alternative wellness solutions are driving category expansion across the market. These trends are becoming key drivers of D2C market trends 2025 and attracting increasing investor interest in high-potential healthcare businesses.
Wholeleaf’s growth story also reflects the increasing importance of D2C brand building stories, D2C product innovation, and D2C revenue growth within India’s startup ecosystem. As consumers seek safer and more effective long-term pain management solutions, companies that combine medical credibility with strong distribution capabilities are well-positioned to capture market share.
With fresh funding on the horizon, expanding retail reach, strong ARR growth, and a growing product portfolio, Wholeleaf is entering its next phase of scale. The company’s continued focus on innovation, scientific validation, and distribution expansion positions it as one of the most promising healthcare-focused startups within India’s fast-growing D2C ecosystem
